Cardiovascular benefits of early sodium‐glucose cotransporter 2 inhibitor use for diabetics with acute myocardial infarction: A nationwide cohort study
Early SGLT2i use in diabetics experiencing acute MI reduced cardiovascular risk, supporting its potential therapeutic use.
Authors
- Hao‐Min Cheng (ORCID: https://orcid.org/0000-0002-3885-6600)
- Gregory Y.H. Lip (ORCID: https://orcid.org/0000-0002-7566-1626)
- Yu‐Hsuan Lee (ORCID: https://orcid.org/0000-0001-7660-3770)
- Tien-Min Chan
- Chian‐Ying Chou
- Yuh‐Lih Chang (ORCID: https://orcid.org/0000-0002-9795-1747)
- Yu‐Shiuan Wang (ORCID: https://orcid.org/0000-0001-7204-1256)
- Chen‐Huan Chen (ORCID: https://orcid.org/0000-0002-9262-0287)
- Hui‐Ju Tsai (ORCID: https://orcid.org/0000-0002-5338-6117)
- Sheng‐Fan Wang (ORCID: https://orcid.org/0000-0002-6467-7366)
- Hsin‐Chen Lee (ORCID: https://orcid.org/0000-0001-7455-9593)
- Chern‐En Chiang
Institutions
- University of Liverpool (GB)
- National Yang Ming Chiao Tung University (TW)
- National Health Research Institutes (TW)
- National Tsing Hua University (TW)
- Taipei Veterans General Hospital (TW)
- Liverpool Heart and Chest Hospital (GB)
- Menninger Clinic (US)
- Taipei Medical University (TW)
- Aalborg University (DK)
Publication Details
- Journal
- British Journal of Clinical Pharmacology
- Published
- 2025-12-14
- DOI
- https://doi.org/10.1002/bcp.70416
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00